Resumption of growth after methionyl-free human growth hormone therapy in a patient with neutralizing antibodies to methionyl human growth hormone.
A 16-5/12 year-old male was diagnosed with classical growth hormone (GH) deficiency at the age of 8-6/12 years and was treated with recombinant methionyl human growth hormone (m-hGH). Height increased from 104.0 cm to 107.4 cm over the first 6 months. After that, for 1 year, he demonstrated poor growth velocity which was found to be secondary to a high titer of GH antibodies with GH binding capacity >2 mg/l. After a 7-month washout period during which no GH was given, at age 11 years he was placed on recombinant methionyl-free human growth hormone (met-free hGH). His height increased 14.9 cm in 11 months (annualized growth rate of 16.2 cm/year). This report illustrates that evaluation of growth failure during GH therapy should include measurement of anti-GH antibodies so that an appropriate alteration of GH therapy can be made if indicated.
Pitukcheewanont
Pisit
P
Childrens Hospital Los Angeles, Department of Pediatrics, The Keck School of Medicine of the University of Southern California, USA. dpisit@chla.usc.edu
Schwarzbach
Liz
L
Kaufman
Francine Ratner
FR
D000293:Adolescent; D000375:Aging; D000906:Antibodies / Q000097:blood*; D001827:Body Height; D019382:Human Growth Hormone / Q000031:analogs & derivatives* / Q000172:deficiency* / Q000276:immunology* / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D017211:Treatment Failure
D000906:Antibodies; D019382:Human Growth Hormone; C447442:somatrem